UPDATE: Medicaid Programs Must Cover Biogen's (BIIB) Aduhelm, CMS Says - Cowen

September 23, 2021 9:35 AM EDT
Get Alerts BIIB Hot Sheet
Price: $264.80 -2%

Rating Summary:
    22 Buy, 19 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 18 | New: 32
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - September 23, 2021 9:39 AM EDT)

Biogen (NASDAQ: BIIB) is on watch as Cowen notes that Medicaid is reinforcing to states that Biogen/Eisai’s Aduhelm (aducanumab) for Alzheimer’s disease must be a covered outpatient drug as the manufacturer has a drug rebate agreement with the program.

Cowen Washington Research Group analyst Eric Assaraf notes, "CMS is advising states they must cover Biogen/Eisai’s Aduhelm (aducanumab) under existing participation by Biogen in the Medicaid drug rebate program, but states can develop their own medical necessity criteria as part of their coverage policy."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, FDA, Hot Comments, Trader Talk

Related Entities

Cowen & Co